🔗 Share this article

While America undertakes historic revisions to its vaccination guidelines, one figure appears in a surprising turn: Høeg, a US-based physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations in the pandemic and has focused upon potential deaths following COVID-19 immunization in her short position at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Schedule

Health officials were set to unveil major revisions to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, according to reports – a major change that would place the US out of alignment with many the global community with little proof for improved outcomes. The planned update has been delayed until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad strengthen their influence at the agency – and it suggests a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for ending certain pediatric immunization guidelines in the US so as to align more in line with the Danish model, a society with universal health coverage and a citizenry about the size of the state of Wisconsin.

In her initial comments, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – as opposed to medication approval.

Doubts Over Qualifications

Dr. Høeg has no apparent track record in medication creation, approval processes or administrative roles, which has been typical for former leaders of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in managing a major agency. She has no expertise in drug approvals.”

Previous heads of CBER would “understand regulatory frameworks and the research of drug development”, said Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who led the center have had.”

CDER has an enormous workload at the FDA, the former commissioner stated.

“Many people just zeroes in on the innovative therapies, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biosimilars program, over-the-counter program and so forth, and all of those have to be looked after,” Woodcock noted. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial administrative component to the role, which oversees more than 5,000 employees. “It is a huge leadership role, if you perform it correctly,” the former official said.

Response and Disputed Initiatives

When asked about questions about Høeg’s credentials and whether this assignment signifies greater collaboration among agency officials on vaccines, a spokesperson stated that the “inquiries are based on inaccurate premises”.

“Her resume matches the functions of her job,” the official explained, noting the time Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the agency head's controversial fast-track approval initiative, a contentious rapid medication authorization process that allegedly concerned her preceding directors. “By what process are these medications being picked for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he stated, “the agency seems to be moving towards laxer oversight of most medications, with the exception of vaccines.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if troubling, track record, critics said. She authored a analysis using non-validated volunteer-provided data to assess the rate of heart inflammation after COVID-19 vaccination. She advised the state of Florida top health official Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the current administration encompassed revising rules for new vaccines and ending “unnecessary” immunizations, she remarked after the election on a audio program. At the agency, Dr. Høeg has allegedly suggested preventing teenage boys from receiving COVID-19 vaccinations.

“She’s an all-around dogmatist who commences with her beliefs and reverse-engineers to fit the evidence in a highly deceptive, untruthful fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|